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Introduction
In more recent series enterococci are responsible for 8-17% of all infective endocarditis (IE) cases [1] [2] [3] [4] [5] . Enterococci as a pathogen in endocarditis is becoming more prevalent as a consequence of the growing number of elderly patients with degenerative heart valve disease, prosthetic heart valves and a higher incidence of enterococcal bloodstream infections originating from the gastrointestinal or urogenital tracts [4] [5] [6] [7] [8] [9] [10] [11] . Infective endocarditis due to enterococci is a serious disease without any apparent improvement in survival during the last decades 12 . No randomized clinical trials, evaluating the treatment of patients with enterococcal IE, are available and current guidelines are therefore based on empirical experience and expert consensus. The international IE guidelines from American Heart Association (AHA) 13 and European Society of Cardiology (ESC) 14 recommend 4-6 weeks of combined antibiotic treatment with aminoglycosides (preferable gentamicin) and an inhibitor of cell wall synthesis (beta-lactam antibiotics or vancomycin). Enterococci are highly tolerant to antibiotic-induced killing, and theoretically these IE patients therefore require prolonged administration of a combination of antibiotics with synergistic effects [15] [16] [17] [18] [19] [20] . However it is well-known, that aminoglycosides are nephrotoxic and prolonged duration of treatment increases the risk of renal function impairment [21] [22] [23] [24] . An important question therefore is, whether or not it is necessary to treat enterococcal IE with gentamicin for as long as 4-6 weeks in order to obtain a sufficient cure rate.
In Denmark new national guidelines on endocarditis were endorsed in January 2007, reducing gentamicin treatment in enterococcal IE from 4-6 weeks to only two weeks. The aim of the present study is to investigate the effects of these new recommendations on relapse and mortality and to evaluate the impact of the reduced duration of gentamicin treatment on renal function.
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Methods

Database
Data from consecutive patients diagnosed with IE in two tertiary heart centers in Copenhagen 
Study population
In the present study we only included patients with definite left-sided enterococcus faecalis IE, T (TTE TE TE) an an nd d tr r tran an anse se seso soph ph pha ag age ea eal l (TEE EE EE) ec ch h hoca a ar rd dio io ogr gr rap aph hy hy. . Du Dura rat tion on n o o of f sy sy ymp mp mpto to om ms ms w w was s s e egi gi gist st ter er ered ed a a as s s ti time me f f fro rom m m ap ap a pe pear ar a an an ance ce ce o of f th th the e e fi fi fir rs r t t t sy sy symp mp mpto o oms ms ms o o of f IE IE IE ( (re re r po po port rted ed ed by by y t the he he p p pat at ati ie ient nt t o o or r th th hei eir r r close family y) ) ) un un unti til l l th th the e e ti ti ime me e o o of f f di di diag ag agno no nosi i is, s 
Kidney function
To estimate kidney function, we approximated patient glomerular filtration rate (eGFR) by calculating the Estimated Endogenous Creatinine Clearance (EECC) at the time of admission, after 14 days of treatment, and at the time of discharge, using the following equations based on the work by Siersbaek-Nielsen et al. 27 and Kampmann et al. 
Follow-up
Through the Danish central patient registry and central registration of death, we were able to accomplish a complete follow up on all-cause mortality and relapse of infection using each patient's civil registration number. The follow up date was 31/7-2012.
Statistics
Continuous data were expressed as mean ± standard deviation (SD). When a normal distribution was uncertain the median and interquartile range (IQR) were given. Binomial data were expressed as frequencies and (%). The statistical evaluation of the 2 groups was performed with a two-sample t-test if the data were normally distributed. When the distribution was skewed, the Mann-Whitney test was used. The dichotomous variables were evaluated using chi-square test groups using Kaplan-Meier survival curves and log-rank test to estimate differences in survival.
In a retrospective power calculation a sample size of 152 patients in each group would be required to provide 80% power to detect a significant difference in primary endpoint of 15 % between the two treatment regimens (assuming 12 month cure rates of 0.60 and 0.75, respectively) with a two-sided significance level of = 0.05.
For all analysis a 2-sided p-value of < 0.05 was considered significant. All 
Results
Patient characteristics
The baseline characteristics for the two groups are presented in Table 1 . The mean patient age was ~70 years in both groups and male gender was predominant with a 4:1 ratio. Co-morbidities were comparable between the two groups including Charlson co-morbidity score. There were no significant differences in predisposing factors between the two groups. Pre-existing valvular disease including prosthetic valve was the most predominant predisposition in both groups. At least one echocardiogram was performed in all patients, and TEE was performed in the vast majority of patients (96%). In both groups aortic location of the infection was most frequently seen, found in approximately half of the cases followed by mitral valve IE and left-sided dual valve IE. There was no difference between the two groups with regard to complications on the initial echocardiographic assessment. Pseudoaneurism or abscess formation was found in 8 patients in each group (Table 1) .
Diagnosis and treatment
The diagnostic delay and doctors delay did not differ significantly between the two groups
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As expected, patients in the group before 2007 received gentamicin for a significantly longer period of time (28 days vs. 14 days, p < 0.001, Table 2 ). The majority of patients received gentamicin in a once daily dose (82%) before and (93%) after January first 2007, respectively.
There was no significant difference between the groups when comparing once vs. twice daily administration (p=0.18, Table 2 ). Only a few patients received gentamicin in a thrice daily regimen. The number of patients undergoing cardiac surgery was similar in the two groups, 15
vs. 14 (p = 0.70).
Complications and survival
The primary end point, event-free 1-year survival from discharge, occurred similarly in the two groups; in 66 % of patients in the group before 2007 and in 69 % of patients in the group after there is still no difference in the primary end point ( Table 3) .
There were no significant differences in non-renal complications between the two groups.
In both groups the most prevalent complication was heart failure followed by stroke and other embolic events ( Table 3) .
Relapse
A total of five patients (6%) had relapse of enterococcus faecalis IE within one year from end of treatment. There was no significant difference in the number of relapses in the two groups; 3
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In-hospital deaths
We assessed the cause of death in each of the 6 fatal cases during hospitalization. In the patients 
Renal function in relation to gentamicin treatment
By calculating the EECC, we estimated the eGFR at admittance, after 14 days of treatment, and at discharge ( Table 5) . Estimated GFR at admittance was similar between the two groups with median values of 66 ml/min vs. 75 ml/min (p=0.22). After 14 days the eGFR was 57 vs. 67 ml/min -still without significant difference (p=0.65). At discharge however, there was a significant difference in eGFR (median: 45 ml/min vs. 66 ml/min, p = 0.008) and the change in eGFR also differed significantly (median: -11 ml/min vs. -1 ml/min, p = 0.009), ( Table 5) .
Discussion
The principal finding of our present pilot study is that antibiotic treatment of non HLAR enterococcus faecalis IE starting out with a beta-lactam combined with 2 weeks of gentamicin wo patients that died, treated after 1 st of January 2007 received ge t ntamicin for l le e ess s th th han an a t t the he he entire course. Again deterioration of renal function was the reason for halting gentamicin. None f f of f t t the he he p p p t at atie ie ient nt nts s ha ha ad d d pe p rsistent enterococcus faecal al ali is i b bacteremia af fte te er ge gent nt nta a amicin was removed.
R Ren na nal function on i in n re rela la l ti ti tion on on to to to g gen en nta ta am m mic c cin t t tre e eatm m me e ent By By y c cal al alcu cu c la lati ti ting n ng t th he he E EE EC CC C, C, we e e es es sti ti tima ma m te ted d th th the e e eG G GFR FR FR a a at t a ad admi mi mitt tt ttan n nce ce c , , af af afte te ter r 14 4 4 d day ay ays s s of of t t tre re reat tme me ment nt, , an n nd d at discharge ( (Ta Ta Tabl bl le e e 5 5). ). ) E E Est t tim im imat ated ed ed G G GFR FR FR a at t t ad ad admi mi mitt tt t an an ance ce e w w was as as s s sim im mil il ilar ar ar b b bet et e we we ween en en t t the he t two wo wo g g gro ro r ups with It is widely acknowledged that enterococci are relatively resistant to antibiotics and therefore it can be challenging to treat enterococcal IE [15] [16] [17] 20 . Since the middle of the last century, in vitro studies, animal studies and many patient reports have demonstrated synergistic effect with better cure rates, when combining a beta-lactam antibiotic with an aminoglycoside [29] [30] [31] [32] [33] [34] . Therefore, this combination has been widely used worldwide and with 4-6 weeks of treatment, 3 month cure rates around 80 percent have been achieved 1,2,7,12,35,36 . Interestingly, in 2007 Gavaldà and colleagues 37 presented an alternative treatment with a 6 week combination of ampicillin and ceftriaxone in enterococcal IE. They treated 43 patients and obtained a 3 month cure rate of 67 % concluding that it could be a reasonable alternative for patients infected with high-level aminoglycoside resistant enterococci or with increased risk of nephrotoxicity.
AHA 13 and ESC 14 guidelines on enterococcal IE, recommend a standard of 4 weeks combined antimicrobial therapy with penicillin (or ampicillin) and gentamicin. If the patient has prosthetic valve IE or the duration of symptoms has been more than 3 months the recommendations are 6 weeks of combined treatment.
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reatment.
The Danish guidelines on treating enterococcal IE were changed in January 2007
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In our study we found no evidence of an association between relapse and PVE, symptoms for more than 3 months or shorter duration of Gentamicin treatment.
It is well-known that gentamicin is nephrotoxic and that longer treatment duration increases the risk of renal function impairment. Based on older studies 7, 34 , demonstrating reversible serum creatinine increases in enterococcal IE patients treated with gentamicin, it has been suggested that the decrease in eGFR is only temporary. However Cosgrove and colleagues 39 have demonstrated that even short-term gentamicin treatment may cause a sustained decrease in creatine clearance, especially among those with initially slightly reduced eGFR.
Another study from our own group by Buchholtz et al. 22 showed only partly reversibility in renal impairment of IE patients during hospitalization, with full restitution in 64 % of the patients. The longer time the patients were treated with gentamicin the greater was the reduction in eGFR and among the patients with the greatest decline only 35 % obtained restitution of renal function at follow-up 22 . A decrease of renal function in IE patients can also be caused by e.g.
glomerulonephritis, septic embolisms and interstitial nephritis 40 . The two groups in the present study are very similar and have all been infected with enterococcus faecalis. Therefore we find it most unlikely that a difference in the occurrence of these renal complications play an important role for the observed difference in the change of eGFR between the two groups. In IE it is recommended to administer gentamicin in 2-3 daily doses (AHA/ESC guidelines). However, the killing effect of gentamicin is related to peak plasma concentration and in other septic diseases gentamicin is therefore given once daily 41, 42 . In a randomized trial of IE using 51 Cr-EDTA clearance as a measure of GFR we demonstrated that a once daily gentamicin dosing regimen had similar efficacy and similar nephrotoxic effect as a twice daily regimen 43 . Therefore, the more simple once daily gentamicin regimen is now recommended for IE treatment in Denmark.
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Other studies [44] [45] [46] have shown that renal function at time of admission is an independent predictor of mortality in patients with IE as well as in patients with left side heart failure 47 .
Therefore, prolonged aminoglycoside treatment in patients with enterococcal IE may unnecessarily place at least some of them in a higher risk group in case of future hospital admissions.
In the present study patients with HLAR enterococcus faecalis IE were omitted, but HLAR is a serious and increasing problem in enterococcal endocarditis with reports comprising up to 28-48% 37,48 of the patients. Decreasing aminoglycoside treatment duration is one important way to limit further development of HLAR.
Implications
Since the length of aminoglycoside treatment has never been accordingly evaluated, and because there is clear evidence of progressive decline in renal function with the length of this treatment, our present data imply that recommendations on duration of aminoglycoside treatment in enterococcus faecalis IE should be revisited.
Limitations
While our study is not a randomized clinical trial, it is a prospectively collected consecutive cohort with a historical control group. The study period was approximately 4 years before and after 1 st of January 2007. The relatively short time period favors standardized treatment regimens with only few changes over time. Our results are limited by the size of the cohorts, and due to the lack of sufficient power, our results need to be interpreted with caution. Nevertheless, we do present the so far largest investigation on the relationship between gentamicin treatment and one year outcome in enterococcus faecalis IE.
According to the power calculation a randomized clinical trial of e. faecalis IE treatment
mplications
Since the length of aminoglycoside treatment has never been accordingly evaluated, and because h her er re e e is is is c cle le lear ar a evi ide de denc n e of progressive decline in re re r n nal function wit it th h th he e e le le length of this treatment, our r pr p esent da ata ta im mp mply ly ly tha ha hat t t re re ec co comm mm mmen en e da da ation n ns on d d du u urat tio io ion n o o of a ami mi ino o ogl glyc yc co os sid id de e e t tr trea eatm tm tmen en e t t t in n n en nte te tero ro oco co c cc cc cus us us f fae ae eca a ali lis s IE IE E s sho hou ul u d d d be be be r r rev evis isit it ited ed ed. would require several hundred patients and since it is a quite rare disease such a trial would be difficult to complete.
Additionally, our study only included 3 patients with symptoms for more than 3 months and therefore no firm conclusions can be drawn for this group of patients. Finally, referral bias may influence our results, as only patients from tertiary centers were included.
Conclusion
Our present pilot study suggests that a recommendation of 2 weeks gentamicin treatment seem adequate and preferable in treating non HLAR enterococcus faecalis infective endocarditis. The longer duration of gentamicin treatment is associated with worse renal function and although the certainty of the clinical outcomes is limited by the sample size, outcomes appear to be no worse.
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